Emcure Pharmaceuticals Q3 Results
- BSE: 544210
- NSE: EMCURE
- ISIN: INE168P01015
- Sector: Biotechnology & Drugs
BSE
1,451.20
-16.90 (-1.15%)
-16.90 (-1.15%)Volume4.54 K
Updated: Thu 5 Mar, 2026 | 15:29:11
NSE
1,452-14.90 (-1.02%)
-14.90 (-1.02%)Volume87.29 K
Updated: Thu 5 Mar, 2026 | 15:29:58
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹2,363.48 Cr.(20.42%)
- Operating Profit₹317.29 Cr.(19.76%)
- Profit After Tax₹230.54 Cr.(49.97%)
- Operating Margin13.42%(-0.55%)
Note: Comparison is on YoY basis
Quarterly - Emcure Pharmaceuticals Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 2,046.19 | 1,718.01 | 5.73% | 1,464.98 | 20.53% |
| Depreciation/ Amortization | 104.68 | 96.90 | 0.04% | 84.39 | 8.13% |
| Operating Income | 317.29 | 283.98 | -5.14% | 202.67 | 19.76% |
| Net Income | 230.54 | 194.57 | -5.31% | 113.45 | 49.97% |
| Other Operating Expenses Total | 553.60 | 476.85 | -0.53% | 420.12 | 22.69% |
| Net Income Before Taxes | 313.79 | 273.41 | -8.09% | 170.96 | 36.48% |
| Total Revenue | 2,363.48 | 2,001.98 | 4.13% | 1,667.64 | 20.42% |
| Selling/ General/ Admin Expenses Total | 387.33 | 355.59 | 0.70% | 332.08 | 5.56% |
| Diluted Normalized EPS | 13.64 | 10.33 | 6.18% | 6.53 | 68.03% |